“…To control for variability generated from PF cytology status, studies evaluating cytology - patients were pooled. Fifteen studies were selected to evaluate the prognostic effects of various endpoints (OS[ 37 , 46 , 10 , 44 , 40 , 41 , 38 ], DFS[ 42 , 26 , 43 , 48 , 47 , 38 ] and PRF[ 46 , 10 , 39 , 45 , 38 , 13 ]) for GC. MAPF + patients had poor prognoses for OS (HR 2.59, 95%CI 1.99–3.37, n = 7, I 2 = 9.2%, P Q = 0.359), DFS (HR 4.92, 95%CI 3.28–7.37, n = 6, I 2 = 7.3%, P Q = 0.370) and PRF (HR 2.81, 95%CI 2.12–3.72, n = 6, I 2 = 35.3%, P Q = 0.172), as shown in Table 2 .…”